Conventional fractionation for half a century has been justified on the basis that 2.0 Gy fractions spare doselimiting late-responding normal tissues to a greater degree than cancerous tissues. Early indications that breast cancer responds more strongly to fraction size than many other common cancers were followed several decades of investigation, but there is now reliable Level I evidence that this is the case. Four randomised trials testing fraction sizes in the range 2.7-3.3 Gy have reported 10-year follow up in almost 8000 patients, and they provide robust estimates of α/β in the range of 3 Gy. The implication is that there are no advantages in terms of safety or effectiveness of persisting with 2.0 Gy fractions in patients with breast cancer. 15-or 16-fraction schedules are replacing the conventional 25-fraction regimen as a standard of care for adjuvant therapy in an increasing number of countries. A number of concerns relating to the appropriateness of hypofractionation in patient subgroups, including those treated post-mastectomy, advanced local-regional disease and/or to lymphatic pathways are addressed. Meanwhile, hypofractionation can be exploited to modulate dose intensity across the breast according to relapse risk by varying fraction size across the treatment volume. The lower limits of hypofractionation are currently being explored, one approach testing a 5-fraction schedule of local-regional radiotherapy delivered in 1 week. 2 of 8 birpublications.org/bjr Br J Radiol;92:20170849 BJR Yarnold
a bit of history
My first exposure to Jack Fowler and Oliver Scott was at the Gray Laboratories and Mount Vernon Hospital in June 1975, during the very first Royal College of Radiologists 1 week radiobiology teaching course organised by Hugh Thomlinson for first year trainees. A few days' contact with these individuals did more than anything else to stimulate in our student group a lasting interest in clinical radiation biology. In the years that followed, Jack Fowler became a leading interpreter of the linear-quadratic model developed by Rodney Withers and colleagues. 1, 2 No better summary exists of the early history of fractionation, including hypofractionation, than that written by Jolian Hendry for a review of UK practices published by the The Royal College of Radiologists in 2006. 3 Interest in hypofractionation applied to primary breast cancer was sparked by a review of super/hyperfractionation (fractions <2.0 Gy) by the Canadian radiation biologist Bruce Douglas through the lens of the still-new linear quadratic model. 4 On the final page of his 11-page manuscript was a single reference to hypofractionation; "For breast cancer, however, the β/α value that can be calculated from published data is about 0.26". Well, that sentence made me jump, since the reciprocal of 0.26 is an α/β-value of 3.8 Gy. The data to which Douglas referred were published by Lionel Cohen in the British Journal of Radiology in 1952. 5 His manuscript combined an analysis of patients treated at the Radiotherapy Department, Johannesburg, with a review of earlier manuscripts describing tumour control in >1000 locally advanced or recurrent breast cancer patients irradiated with a range of fractionation regimens (Figure 1 ). Douglas does not describe how he reanalysed Cohen's data, but he will have controlled for time-related effects by estimating median tumour control doses for subgroups of patients treated to different total doses in daily fractions over similar time periods. randomised trials of adJuvant hyPofractionation A 2016 systematic overview of fraction size in breast radiotherapy in the Cochrane Database of Systematic Reviews identified four trials (three from UK and one Canadian) reporting 10 year outcomes of hypofractionation plus two further studies (N = 908 and 47) reporting 3.5 year results. 6 These trials will be summarised only briefly, since they have been published for several years. [7] [8] [9] [10] [11] [12] [13] All adopted a control regimen of 50 Gy in 25 fractions following primary surgery, mostly breast conservation surgery, and tested fraction sizes in the range 2.7-3.3 Gy. The UK START-Pilot (-P) and START-A trials were three-arm studies designed to generate direct estimates of α/β for local cancer control and normal tissue responses unconfounded by differences in treatment time (5 weeks), whereas the UK START-B and Ontario trials were pragmatic two-group comparison testing non-inferiority of 15-and 16-fraction regimens (2.7 Gy per fraction) over 3 and 3.2 weeks in terms of local tumour control and adverse effects. Patient and treatment characteristics of these four trials are summarised in Table 1 .
Rates of local tumour relapse in these trials are summarised in Table 2 , from which a couple of points can be made. The two test dose regimens in START-P were 13-fraction regimens estimated to be isoeffective with 50 Gy in 25 fractions based on α/β-values A second point to note in Table 2 is that START-B confirmed non-inferiority of the 15-fraction regimen based on an upper 95% confidence interval (CI) for local relapse at 10 years. The results of the Ontario trial were consistent with this result. A recent post hoc evaluation of the better-than-expected 3.8% point estimate for local relapse rate 10 years after 40 Gy in 15 fractions compared to 5.2% after 50 Gy in 25 fractions in START-B raises the possibility of a time effect for local control after adjuvant breast radiotherapy. Better-than-expected because the 3-week schedule is equivalent to 46 Gy in 23 fractions assuming α/β = 3 Gy, as estimated by START-P and -A trials, in which all patient groups had 5 weeks of radiotherapy. A hypothesis-generating analysis postulates 0.65 Gy wasted dose per day, when 2 Gy fractions are used. 14 Table 3 summarises secondary end points, including moderate or marked adverse effects of breast shrinkage and cosmesis in the Ontario trial.
Estimates of α/β for local tumour control and late adverse effects based on 10year follow up of 5861 patients in the START-P and START-A/B trials are summarised in Table 4 . The estimates are consistent with hypothesis that 2 Gy fractions are as gentle on breast cancer as they are on healthy tissues. This 15 This schedule is currently standard of care for all UK patients prescribed adjuvant local or local-regional radiotherapy for operable breast cancer. If a tumour bed boost dose is indicated in patients with high risk features, an additional 13.5 Gy in five fractions of 2.7 Gy delivers the equivalent of 14 Gy in seven fractions of 2 Gy, assuming an α/β of 3 Gy.
any concerns?
Arguments against routine adoption of 15-or 16-fraction regimens given Level I evidence of safety and effectiveness are often expressed in terms of underrepresented patient subgroups, begging questions as to where the burden of proof lies in an era of rapid changes in patient management. Subgroups are clearly important for endocrine and biological agents that target cancer-specificmechanisms operative in defined subsets of tumours. Tumour type-specific molecular pathways targeted by endocrine and other systemic agents stand in contrast to a central role for DNA double strand break processing and repair in normal and malignant tissue responses to fractionated radiotherapy, possibly including immune responses. 16 If standard fractionation is prescribed with confidence before, after or alongside new systemic agents, e.g. there is every likelihood of safety if a hypofractionation regimen is used, an expectation that can be prospectively monitored. Funding tariffs for radiotherapy can also be barriers to adoption of hypofractionation, but putting this aside, what other concerns are expressed?
Are the trial patient and tumour characteristics representative of the population?
The Ontario trial population represents the largest single subgroup of females referred for adjuvant radiotherapy, namely females ≥50 years treated by tumour excision for pT1-2pN0M invasive carcinoma, representing at least one-half of all patients prescribed post-operative adjuvant radiotherapy for early breast cancer in many countries. The eligibility criteria for the START trials were broader, only excluding patients having immediate breast reconstruction or prescribed concurrent cytotoxic chemotherapy. Table 5 shows patient and treatment characteristics for the 5861 patients entered in the three START trials, confirming features representative of the contemporary UK population, including the proportion of patients prescribed adjuvant chemotherapy, 1998-2002. The hazard ratios shown in Figure 2 raise no concerns for any particular subgroup, with point estimates <1 for females under 50 years, those treatment by mastectomy, those with node positive tumours or high tumour grade and females prescribed cytotoxic therapy. On this basis, there is no identifiable reason to withhold radiotherapy from any group of patients, and if this policy is maintained for a population with characteristics broadly comparable with those tested in the hypofractionation trials, the overall results will be those of a safe, effective, convenient and even less expensive therapy. What about the heart? No excess of cardiac damage has been suggested after hypofractionation in the START or Ontario trials, although the small number of cardiac events limits the power of formal comparisons. It is easy to model the impact of hypofractionation by assuming different α/β-values for the heart, Table 6 , where it is clear that even assuming a sensitivity to fraction size as low as 1.5 Gy, the equivalent total dose delivered in 2 Gy fractions of 40 Gy in 15 fractions is lower than the historical standard of 50 Gy in 25 fraction. 17 In practice, the challenge is to protect the heart regardless of radiotherapy regimen by adopting breath hold or other heart-sparing technique. 18 The heavy-breasted patient-"triple trouble"? It is a myth that dose inhomogeneity in the breast poses a risk to patients prescribed hypofractionation. Look at Table 7 , where the impact of dose inhomogeneity is illustrated in relation to a partial volume receiving 105%. 19 If 3.2 Gy fractions are used as illustration, 13 fractions deliver the equivalent of 50 Gy in 25 fractions, corresponding to α/β = 3 Gy and consistent with results of the START-A and Ontario trials. Double trouble as described by Withers is a problem, no doubt about that, but modest hypofractionation does not make this worse i.e. there is no "triple trouble".
After mastectomy?
Why some people worry that removing the breast might alter the fractionation sensitivity of overlying skin and underlying ribcage is unclear, but this is an occasional concern expressed at conferences. Several hundred mastectomy patients (N = 513) were entered in the START trials, and comparisons were not powered for statistical analysis. However, just looking at the hazard ratios and 95% CIs for selected patient-reported outcomes in START-A in Table 8 raise no cause for concern. 20 The hypofractionation trials were conducted before the current era of oncoplastic surgery, but there are no identifiable reasons to avoid hypofractionation in this subgroup either. As emphasised above, even assuming α/β of 1.5 , 40 Gy in 15 fractions is expected to generate milder late adverse effects than 50 Gy in 25 fractions.
Is there any reason to avoid the lymphatics?
Only 470 patients were prescribed lymphatic radiotherapy in the START trials, most commonly to supraclavicular fossa, and extending to upper axillary levels in a small minority. Variable volumes of Level I/II axilla would have been included the tangential beams to the breast, despite Level I/II surgical dissection in >90% patients. There was no suggestion of enhanced shoulder stiffness or arm oedema associated with hypofractionation in the 10-year START assessments, but these included all patients regardless of lymphatic radiotherapy. 13 A retrospective analysis Table 7 . 'Triple trouble' in heavy-breasted patients is not a concern, either 19 of patient-reported outcomes in those prescribed lymphatic radiotherapy raises no suggestion of enhanced arm or shoulder dysfunction associated with hypofractionation (Haviland, in press). With regard to the brachial plexus, no cases were recorded after 40 Gy in 15 fractions in the START-B trial, and modelling the expected impact of this schedule assuming a very low value of α/β = 1.5 Gy (as in Table 6 for heart), suggests that this regimen should be gentler on the brachial plexus than 50 Gy in 25 fractions. As comprehensive lymphatic radiotherapy is introduced that exploits improved planning and treatment techniques, the risk of "triple trouble" is as insignificant for brachial plexus as it is for heavy-breasted patients. In other words, if oncologists are confident in prescribing 50 Gy in 25 fractions to contemporary lymphatic treatment volumes, they should be confident to prescribe 40 Gy in 15 fractions.
Breast dose inhomogeneity

Trials tested only adjuvant hypofractionation
Oxygen status, proliferative kinetics and other parameters change according to disease bulk, raising a question about hypofractionation in patients with clinical disease. There are no randomised data, but the starting point of this manuscript was an analysis of >1000 patients with locally advanced or locally recurrent disease treated with a wide range of fractionation regimens deriving an α/β-value of 3.8 Gy, which is comparable with that generated by randomised trials in the adjuvant setting. Bulky prostatic carcinomas are also sensitive to fraction size, so on balance it seems very likely that breast cancer is too, but it would certainly be beneficial to put this hypothesis to test in randomised trials. 21
hyPofractionation and dose intensity modulation
Since hypofractionation to the whole breast/chest wall is a standard of care in an increasing number of countries, it carries implications for how a tumour bed boost doses should be delivered. There seems little point in retaining fraction sizes of 2.0 Gy, if modulation of fraction size can achieve the same outcomes. The UK IMPORT HIGH trial (N = 2,658) tests the hypothesis that concomitant boost is as safe and non- BJR Review article: Changes in radiotherapy fractionation-breast cancer inferior to standard sequential boost techniques (Figure 3a ). 22 All patients were treated using megavoltage X-rays using forward or inverse planned intensity modulated radiotherapy localised using image-guidance to visualise titanium ligaclips inserted in the tumour bed. Target volumes for whole breast and boost volumes were defined prior to randomisation. The boost dose intensity in Test 1 was chosen on the basis that it was expected to be isoeffective with control assuming α/β = 3 Gy, whereas the dose intensity to whole breast in Test 1 was reduced to reflect the lower tumour burden and low recurrence risk outside the boost volume. The dose spared in Test 1 was "moved" into the boost volume in Test 2, which received approximately the same integral total breast dose as Control ( Figure 3b ). It is hoped that patient reported outcomes and clinical evaluations of adverse effects and local tumour control will inform more effective distributions of breast dose leading to further improvement in therapeutic ratio.
Hypofractionation has also been applied to test dose intensity reduction in females judged at low risk of local relapse after breast conservation surgery (Figure 4a,b ). In the recently published IMPORT LOW trial, non-inferiority for local control was confirmed and fewer adverse effects were reported in Test Group 2 compared to Group 1 or whole breast radiotherapy. 23 what are the limits of whole breast hyPofractionation? In principle, since the fractionation sensitivity of breast cancer is comparable to that of the dose-limiting normal tissues, it is reasonable to consider if a single fraction is the logical end point of hypofractionation in breast cancer, at least in the adjuvant setting where reoxygenation may not need to be exploited. Single high dose rate intraoperative irradiation of the tumour bed using megavoltage electrons or orthovoltage X-rays tested in the ELIOT and TARGIT trials represent limited examples of this approach, but the results are so far difficult to interpret given very uncertain dosimetry and treatment volumes. 24, 25 The UK FAST trial tested two total doses (30 & 28.5 Gy) of a 5-fraction regimen (3.0 & 5.7 Gy per fraction) delivering one fraction per week against 50 Gy in 2.0 Gy fractions to whole breast in 915 females ≥50 years following complete microscopic local resection of pT1-2pN0M0 disease. 26 Median 3 year analyses of adverse effects (primary end point) were consistent with α/β of 3 Gy, as reported by the START trials, although the point estimate was slightly lower at 2.6 Gy [95% CI (1.4-3.7)]. If a point estimate of 2.6 Gy is assumed, it may reflect the much lower rate of moist desquamation (11% after 50 Gy vs 2% after 28.5 Gy) and reduced risk of consequential late effects, particularly telangiectasia in the inframammary fold. Consequential late effects share the same high α/β-value as the epidermal depletion that causes them and if present will tend to increase the estimate of α/β-value. At the time of last reporting (median 3 years), only two local relapses had been recorded.
The early results of the FAST trial informed the design of the UK FAST-Forward trial (N = 4000) testing two dose levels of a 5fraction regimen delivered in 5 days against the current UK standard of 40 Gy in 15 fractions in patients prescribed whole breast or post-mastectomy irradiation after primary surgery ( Figure  9 ). 27 The trial recruited between 2012 and 2014 and remains in follow up. A lymphatic subprotocol is currently recruiting with arm swelling and shoulder mobility as primary endpoints.
the future? Figure 5 shows the timeline of the UK adjuvant breast radiotherapy trials referred to in this review.
A possible outcome is a 1 week schedule of dose intensity modulated whole or partial breast radiotherapy that not only improves the balance of local cancer control and adverse effects but also reduces the physical, emotional and economic burdens of classical treatment schedules. The trials discussed here, and many other radiotherapy trials worldwide, undoubtedly owe a debt to the inspiration and encouragement offered by Jack Fowler and Oliver Scott to several generations of radiation oncologists. Table 9 funding I acknowledge NHS funding to the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research. 
